-- Auxilium, General Moly, MannKind, Sirius: U.S. Equity Movers
-- B y   I n y o u n g   H w a n g
-- 2010-12-28T21:15:02Z
-- http://www.bloomberg.com/news/2010-12-27/chemed-dresser-rand-fannie-mae-kodak-u-s-equity-preview.html
Shares of the following companies
had unusual moves in U.S. trading. Stock symbols are in
parentheses, and prices are as of 4 p.m. in New York.  Rare-earth mineral companies rallied after China cut its
export quotas by 11 percent in the first round of permits for
2011.  General Moly Inc.  (GMO US) climbed 7.8 percent to $6.36,
the highest level since September 2008.  Rare Element Resources
Ltd.  (REE US) rose 10 percent to $12.94, the highest price since
at least June 2004.  Auxilium Pharmaceuticals Inc.  (AUXL US) slipped 2.5
percent, the most since Nov. 12, to $20.91.  Repros Therapeutics
Inc.  (RPRX US) said it reanalyzed data from a previous trial,
which showed Androxal significantly boosted testosterone levels
in men with certain hormone levels compared with the placebo.
Auxilium’s Testim is a competing treatment.  BioSante Pharmaceuticals Inc.  (BPAX US) fell 20 percent to
$1.61 for the biggest drop in the Russell 2000 Index. The
developer of products for female sexual health and oncology said
it’s selling 10.6 million shares of common stock and warrants to
purchase as much as 5.3 million additional shares.  Caraco Pharmaceutical Laboratories Ltd.  (CPD US) fell 10
percent to $4.63 for the third-biggest drop in the Russell 2000.
The generic drugmaker said Sun Pharmaceutical Industries Ltd.
exercised an option to end two distribution agreements, citing
competitive pricing pressures. The agreements will expire in
January 2012.  General Motors Co.  (GM US) rose 2.1 percent to $35.32. The
automaker was rated “overweight” in new coverage at JPMorgan
Chase & Co., Barclays Plc and Morgan Stanley. GM was rated
“outperform” at Credit Suisse Group AG and RBC Capital
Markets, which also initiated coverage of the stock. Citigroup
Inc. and Bank of America Corp. have a new “buy” recommendation
for GM.  KBR Inc.  (KBR US) rallied 4.7 percent to $30.90, the
highest price since July 2008. The construction manager was
raised to “buy” from “hold” at BB&T Capital Markets.  MannKind Corp.  (MNKD US) gained 3.3 percent, the most in
two weeks, to $8.23. U.S. regulators delayed a decision on the
company’s inhaled insulin. The biotechnology company founded by
the billionaire inventor  Alfred Mann  said the Food and Drug
Administration isn’t able to meet tomorrow’s scheduled deadline
for action on the diabetes drug, Afrezza, and will need about
four more weeks to complete its evaluation.  Santarus Inc.  (SNTS US) rose 3.2 percent to $3.27, the
highest since Nov. 8. The drugmaker and its Dutch partner
Pharming Group NV asked U.S. regulators to review their medicine
Rhucin to treat acute angioedema attacks.  Sirius XM Radio Inc.  (SIRI US) jumped 5.2 percent to $1.63,
the biggest move in the Russell 1000 Index.  Martin Pyykkonen  of
Wedge Partners LLC said a recent FCC ruling on net neutrality is
a catalyst for the strength. The analyst said this was a
perceived threat for several years.  To contact the reporter on this story:
 Inyoung Hwang  at   ihwang7@bloomberg.net .  To contact the editor responsible for this story:
Nick Baker at   nbaker7@bloomberg.net . 